Study title: Open, multicentric, post marketing surveillance study of GlaxoSmithKline Biologicals’ Vi polysaccharide typhoid vaccine (TYPHERIXÔ) injected in healthy children and adults according to the Indian prescribing information.
Type of medicine: Non-centrally authorised vaccines | |||||
Therapeutic area: | |||||
Brands: Please see report, Please see report, Please see report | |||||
MAH holders: Please see report | |||||
Assessment: | |||||
Active substance: Vi polysaccharide of Salmonella typhi | |||||
ATC code: | |||||
Document link: | |||||
Document date: 2011-09-28 | |||||
Study number: 219550/012 (TYPH-012) | |||||
EudraCT number: | |||||
Scope of study: CLINICAL | |||||
Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
- | - | - | Y | Y |